<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03676296</url>
  </required_header>
  <id_info>
    <org_study_id>NCD001.0</org_study_id>
    <nct_id>NCT03676296</nct_id>
  </id_info>
  <brief_title>Effect of Puerarin on Heart Health in Men</brief_title>
  <official_title>Effect of Puerarin Supplementation on Cardiovascular Disease Risk Factors in Men: a Randomized, Double-blind, Placebo-controlled, 2-way Crossover Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The University of Hong Kong</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Health and Medical Research Fund</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>The University of Hong Kong</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to assess the effect of puerarin supplementation on cardiovascular disease&#xD;
      risk factors in men.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Objectives: To assess the effect of puerarin supplementation on cardiovascular disease risk&#xD;
      factors in men.&#xD;
&#xD;
      Study design: A randomized, double-blind, placebo-controlled, 2-way crossover trial of&#xD;
      12-week puerarin supplementation.&#xD;
&#xD;
      Study subjects: 234 Hong Kong Chinese men aged 18-50 years without a history of&#xD;
      cardiovascular disease.&#xD;
&#xD;
      Intervention: After assessing eligibility, all participants will be randomized to take a&#xD;
      puerarin supplement in granules (90.2 mg daily) or a placebo, followed by a 4-week wash-out&#xD;
      period, after which participants will be crossed over to the other intervention.&#xD;
&#xD;
      Primary outcomes: Lipid profile (total cholesterol, low density lipoprotein (LDL)&#xD;
      cholesterol, high density lipoprotein (HDL) cholesterol, triglycerides).&#xD;
&#xD;
      Secondary outcomes: Cardiovascular disease risk factors, such as blood pressure and fasting&#xD;
      glucose, as well as some potential mediating pathways, such as testosterone.&#xD;
&#xD;
      Methods: An intention to treat analysis will be used, assuming no changes in baseline value&#xD;
      for missing follow up values. Differences in outcomes between supplementation and placebo&#xD;
      within participants will be compared using a paired t-test, after checking for the&#xD;
      possibility of a carryover effect.&#xD;
&#xD;
      Expected results: The short-term effect of puerarin on cardiovascular disease risk factors in&#xD;
      men will be obtained so as to confirm or refute previous trials usually with small sample&#xD;
      sizes that suggest puerarin may improve lipid profile and reduce testosterone. The findings&#xD;
      will also add evidence about the effects of puerarin on other potentially relevant risk&#xD;
      factors, such as blood pressure, fasting glucose and testosterone, as well as some related&#xD;
      biomarkers.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 5, 2018</start_date>
  <completion_date type="Actual">April 17, 2021</completion_date>
  <primary_completion_date type="Actual">April 17, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in total cholesterol</measure>
    <time_frame>Baseline, 12 weeks, 16 weeks and 28 weeks</time_frame>
    <description>Mean difference in total cholesterol (mmol/L)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in low density lipoprotein (LDL) cholesterol</measure>
    <time_frame>Baseline, 12 weeks, 16 weeks and 28 weeks</time_frame>
    <description>Mean difference in LDL cholesterol (mmol/L)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in high density lipoprotein (HDL) cholesterol</measure>
    <time_frame>Baseline, 12 weeks, 16 weeks and 28 weeks</time_frame>
    <description>Mean difference in HDL cholesterol (mmol/L)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in triglycerides</measure>
    <time_frame>Baseline, 12 weeks, 16 weeks and 28 weeks</time_frame>
    <description>Mean difference in triglycerides (mmol/L)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in blood pressure</measure>
    <time_frame>Baseline, 12 weeks, 16 weeks and 28 weeks</time_frame>
    <description>Mean difference in systolic and diastolic blood pressure (mmHg)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in fasting glucose</measure>
    <time_frame>Baseline, 12 weeks, 16 weeks and 28 weeks</time_frame>
    <description>Mean difference in fasting glucose (mmol/L), with log transformation if appropriate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in testosterone</measure>
    <time_frame>Baseline, 12 weeks, 16 weeks and 28 weeks</time_frame>
    <description>Mean difference in testosterone (nmol/L), with log transformation if appropriate</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">217</enrollment>
  <condition>Cardiovascular Disease Risk Factors</condition>
  <arm_group>
    <arm_group_label>Puerarin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Puerarin (90.2 mg daily) in granules</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo in granules</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Puerarin</intervention_name>
    <description>Puerarin (90.2 mg daily) in granules (as well as excipients) taken orally for 12 weeks</description>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_label>Puerarin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo in granules (with the same excipients as the puerarin supplement but without puerarin) taken orally for 12 weeks</description>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_label>Puerarin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Men&#xD;
&#xD;
          -  Aged 18 to 50 years&#xD;
&#xD;
          -  Chinese ethnicity&#xD;
&#xD;
          -  Willing to make return visits&#xD;
&#xD;
          -  Not currently taking any traditional Chinese medicine (including puerarin)&#xD;
             supplementation&#xD;
&#xD;
          -  Not currently receiving hormone replacement therapy, such as testosterone replacement&#xD;
             therapy, in the past 12 months&#xD;
&#xD;
          -  Free of any congenital diseases&#xD;
&#xD;
          -  Free of any infectious diseases e.g. seasonal influenza&#xD;
&#xD;
          -  With no history of any chronic diseases including coronary heart disease (ischemic&#xD;
             heart disease), myocardial infarction (heart attack), stroke, diabetes and cancer&#xD;
&#xD;
          -  Have a 10-year risk of ischemic heart disease of less than 10%&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Women&#xD;
&#xD;
          -  Men, who did not meet the aforementioned inclusion criteria, and/or unable or&#xD;
             unwilling to provide consent&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gabriel M Leung, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>The University of Hong Kong</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The University of Hong Kong</name>
      <address>
        <city>Hong Kong</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>September 11, 2018</study_first_submitted>
  <study_first_submitted_qc>September 17, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">September 18, 2018</study_first_posted>
  <last_update_submitted>April 27, 2021</last_update_submitted>
  <last_update_submitted_qc>April 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 29, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>The University of Hong Kong</investigator_affiliation>
    <investigator_full_name>Professor Gabriel Matthew Leung</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Puerarin</keyword>
  <keyword>Lipids</keyword>
  <keyword>Testosterone</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cardiovascular Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Puerarin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

